Human medicinehttps://www.ema.europa.eu/en/homepageHuman medicineen-gbCopyright: (C) European Medicines AgencySun, 30 Jun 2024 04:03:29 +0200Fri, 24 May 2024 17:05:00 +0200Human medicines European public assessment report (EPAR): Vyvgart, efgartigimod alfa, Date of authorisation: 10/08/2022, Revision: 7, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/vyvgartHuman medicines European public assessment report (EPAR): Vyvgart, efgartigimod alfa, Date of authorisation: 10/08/2022, Revision: 7, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/vyvgartFri, 24 May 2024 17:05:00 +0200Human medicineVyvgart : EPAR - Product Informationhttps://www.ema.europa.eu/system/files/documents/product-information/ema-combined-h-5849-en_1.pdfVyvgart : EPAR - Product Informationhttps://www.ema.europa.eu/system/files/documents/product-information/ema-combined-h-5849-en_1.pdfFri, 24 May 2024 12:38:00 +0200Human medicineOpinion/decision on a Paediatric investigation plan (PIP): Vyvgart, Efgartigimod alfa, decision type: W: decision granting a waiver in all age groups for all conditions or indications, PIP number: P/0013/2023https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002597-pip09-22Opinion/decision on a Paediatric investigation plan (PIP): Vyvgart, Efgartigimod alfa, decision type: W: decision granting a waiver in all age groups for all conditions or indications, PIP number: P/0013/2023https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002597-pip09-22Tue, 06 Feb 2024 15:17:30 +0100Human medicine